Basic Information
AbCheck provides a unique source of therapeutic antibodies, possessing one of the most versatile technology platforms in the industry. We deliver high-quality drug candidates through discovery collaborations or strategic research partnerships based on flexible business terms, including royalty-free agreements. We generate target-specific human antibody domains that can be utilized in various therapeutic formats. Founded in 2009, AbCheck is a spin-off from Affimed's technology discovery platform. AbCheck is a wholly-owned subsidiary of Affimed GmbH, a biopharmaceutical company developing highly targeted cancer immunotherapies.